DE69939956D1 - Verwendung von Myoblasten zur Herstellung eines Medikaments zur Behandlung der stressbedingten Harninkontinenz - Google Patents
Verwendung von Myoblasten zur Herstellung eines Medikaments zur Behandlung der stressbedingten HarninkontinenzInfo
- Publication number
- DE69939956D1 DE69939956D1 DE69939956T DE69939956T DE69939956D1 DE 69939956 D1 DE69939956 D1 DE 69939956D1 DE 69939956 T DE69939956 T DE 69939956T DE 69939956 T DE69939956 T DE 69939956T DE 69939956 D1 DE69939956 D1 DE 69939956D1
- Authority
- DE
- Germany
- Prior art keywords
- medicament
- manufacture
- myoblasts
- urinary incontinence
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
- C12N5/0659—Satellite cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8391798P | 1998-05-01 | 1998-05-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69939956D1 true DE69939956D1 (de) | 2009-01-02 |
Family
ID=22181500
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69939956T Expired - Lifetime DE69939956D1 (de) | 1998-05-01 | 1999-04-30 | Verwendung von Myoblasten zur Herstellung eines Medikaments zur Behandlung der stressbedingten Harninkontinenz |
DE69936785T Expired - Lifetime DE69936785D1 (de) | 1998-05-01 | 1999-04-30 | Zellvermittelte genverabreichung durch verwendung von aus muskeln derivierten zellen zur behandlung der knochen-verwandten verletzung oder störung |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69936785T Expired - Lifetime DE69936785D1 (de) | 1998-05-01 | 1999-04-30 | Zellvermittelte genverabreichung durch verwendung von aus muskeln derivierten zellen zur behandlung der knochen-verwandten verletzung oder störung |
Country Status (8)
Country | Link |
---|---|
EP (3) | EP2075002B1 (de) |
AT (2) | ATE414524T1 (de) |
AU (1) | AU3775799A (de) |
CA (1) | CA2330660C (de) |
DE (2) | DE69939956D1 (de) |
DK (2) | DK1604674T3 (de) |
ES (2) | ES2419029T3 (de) |
WO (1) | WO1999056785A2 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6866842B1 (en) | 1998-05-01 | 2005-03-15 | University Of Pittsburgh | Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction |
US7115417B1 (en) | 1998-05-01 | 2006-10-03 | Chancellor Michael B | Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof |
US6706682B2 (en) | 1999-01-21 | 2004-03-16 | The Trustees Of Columbia University In The City Of New York | Uses of vascular endothelial growth factor in the treatment of erectile dysfunction |
US6315992B1 (en) | 1999-06-30 | 2001-11-13 | Tissuegene Co. | Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1 |
WO2000066177A1 (en) * | 1999-05-03 | 2000-11-09 | Tissuegene Co. | GENE THERAPY USING TGF-$g(b) |
US7338655B1 (en) | 1999-06-30 | 2008-03-04 | Tissuegene, Inc. | Gene therapy using TGF-β |
EP1210102B1 (de) * | 1999-08-19 | 2010-04-07 | Applied Protein Sciences, LLC | Tgf-alpha polypeptide, funktionelle fragmente und methoden zu deren verwendung |
US20020193301A1 (en) | 1999-08-19 | 2002-12-19 | Stem Cell Pharmaceuticals, Inc. | TGF-alpha polypeptides, functional fragments and methods of use therefor |
DK1272204T3 (da) | 2000-04-14 | 2007-09-10 | Univ Pittsburgh | Forstærkning og bulking af blödt væv og knoglevæv under anvendelse af muskelafledte progenitorceller, præparater deraf og behandling dermed |
FR2810045B1 (fr) * | 2000-06-07 | 2004-09-03 | Assist Publ Hopitaux De Paris | Procede d'obtention de population cellulaires caracterisees d'origine musculaire et utilisations |
JP4680483B2 (ja) | 2001-02-23 | 2011-05-11 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 組織および臓器の治療および修復に用いるための幹細胞マトリックスの迅速な調製方法 |
WO2004096245A2 (en) * | 2003-04-25 | 2004-11-11 | The University Of Pittsburgh | Muscle derived cells (mdcs) for promoting and enhancing nerve repair and regeneration |
JP5395672B2 (ja) † | 2006-11-28 | 2014-01-22 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | 心臓病理学を処置するための筋肉由来の細胞およびその作製法および使用法 |
AU2007334331B2 (en) | 2006-12-18 | 2014-05-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same |
US20100158875A1 (en) | 2006-12-18 | 2010-06-24 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same |
JP5425641B2 (ja) | 2007-01-11 | 2014-02-26 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | 尿路病状の処置のための筋由来細胞ならびにその作製および使用の方法 |
WO2008157059A1 (en) * | 2007-06-15 | 2008-12-24 | Ethicon, Inc. | Tissue fragment compositions for the treatment of incontinence |
CA2734858C (en) * | 2008-08-18 | 2019-01-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof |
WO2014040030A1 (en) * | 2012-09-10 | 2014-03-13 | Wake Forest University Health Sciences | Urine stem cells for skeletal muscle generation and uses thereof |
EP3511412A1 (de) | 2018-01-12 | 2019-07-17 | Genethon | Genetisch modifizierte hematopoietische stammzellen als plattform fuer systemische proteinexpression |
US10610280B1 (en) | 2019-02-02 | 2020-04-07 | Ayad K. M. Agha | Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat |
WO2020238961A1 (en) * | 2019-05-29 | 2020-12-03 | Institute Of Zoology, Chinese Academy Of Sciences | Compositions and use of engineered myogenic cells |
WO2024115761A1 (en) | 2022-12-01 | 2024-06-06 | Universität Zürich | Method of preparing a mass culture of muscle precursor cells (mpcs) and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5130141A (en) * | 1988-05-24 | 1992-07-14 | Law Peter K | Compositions for and methods of treating muscle degeneration and weakness |
US5538722A (en) | 1989-06-13 | 1996-07-23 | Stanford University | Isolation, growth, differentiation and genetic engineering of human muscle cells |
US5658565A (en) | 1994-06-24 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Inducible nitric oxide synthase gene for treatment of disease |
JPH08503852A (ja) | 1992-11-25 | 1996-04-30 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブハイヤー エデュケーション | ヒト誘導性一酸化窒素シンターゼのcDNAクローンおよびその作製方法 |
US5594032A (en) * | 1994-11-10 | 1997-01-14 | Gonzalez-Cadavid; Nestor F. | Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA |
SG74036A1 (en) * | 1994-12-13 | 2000-07-18 | Peter K Law | Instrument for cell culture |
US6150338A (en) * | 1997-02-13 | 2000-11-21 | Albert Einstein College Of Medicine Of Yeshiva University | Gene therapy for alleviating erectile dysfunction |
-
1999
- 1999-04-30 DK DK05000057T patent/DK1604674T3/da active
- 1999-04-30 DE DE69939956T patent/DE69939956D1/de not_active Expired - Lifetime
- 1999-04-30 AT AT05000057T patent/ATE414524T1/de active
- 1999-04-30 DK DK08169379.8T patent/DK2075002T3/da active
- 1999-04-30 EP EP08169379A patent/EP2075002B1/de not_active Revoked
- 1999-04-30 ES ES08169379T patent/ES2419029T3/es not_active Expired - Lifetime
- 1999-04-30 ES ES05000057T patent/ES2319660T3/es not_active Expired - Lifetime
- 1999-04-30 DE DE69936785T patent/DE69936785D1/de not_active Expired - Lifetime
- 1999-04-30 AT AT99920202T patent/ATE369141T1/de not_active IP Right Cessation
- 1999-04-30 EP EP05000057A patent/EP1604674B1/de not_active Revoked
- 1999-04-30 EP EP99920202A patent/EP1113807B1/de not_active Revoked
- 1999-04-30 CA CA2330660A patent/CA2330660C/en not_active Expired - Lifetime
- 1999-04-30 AU AU37757/99A patent/AU3775799A/en not_active Abandoned
- 1999-04-30 WO PCT/US1999/009451 patent/WO1999056785A2/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
DE69936785D1 (de) | 2007-09-20 |
EP2075002A3 (de) | 2009-07-08 |
EP1604674B1 (de) | 2008-11-19 |
ATE414524T1 (de) | 2008-12-15 |
WO1999056785A2 (en) | 1999-11-11 |
ES2319660T3 (es) | 2009-05-11 |
ES2419029T3 (es) | 2013-08-19 |
DK2075002T3 (da) | 2013-05-21 |
AU3775799A (en) | 1999-11-23 |
EP1113807B1 (de) | 2007-08-08 |
EP1604674A3 (de) | 2005-12-21 |
EP2075002A2 (de) | 2009-07-01 |
EP1113807A2 (de) | 2001-07-11 |
CA2330660C (en) | 2012-04-10 |
DK1604674T3 (da) | 2009-03-23 |
EP1604674A2 (de) | 2005-12-14 |
CA2330660A1 (en) | 1999-11-11 |
EP2075002B1 (de) | 2013-02-13 |
WO1999056785A3 (en) | 2001-04-19 |
ATE369141T1 (de) | 2007-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69939956D1 (de) | Verwendung von Myoblasten zur Herstellung eines Medikaments zur Behandlung der stressbedingten Harninkontinenz | |
DE69524679D1 (de) | Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure | |
DE69310065D1 (de) | Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose | |
DE60023043D1 (de) | (S,S)-Reboxetin zur Behandlung von Inkontinenz | |
DE122005000002I1 (de) | Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz. | |
DE122005000005I1 (de) | Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz. | |
DE69435330D1 (de) | Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen | |
DE69934813D1 (de) | Verwendung von gaba analogen zur herstellung eines arzneimittels zur behandlung von manie und bipolaren erkrankungen | |
ATE277899T1 (de) | 8-8,6-6 und 6-8 catechin und epicatechin dimere und verfahren zu ihrer herstellung | |
DE69424009D1 (de) | Verwendung von (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidinacetamid zur Herstellung eines Medikaments zur Behandlung von Angst | |
DE69707372D1 (de) | Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne | |
DE69910202D1 (de) | EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden | |
DE69635305D1 (de) | Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma | |
DE60015508T2 (de) | C-16 ungesätigte fp-selektive prostaglandin analoge | |
DE69423577D1 (de) | Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingte Störungen. | |
ATE180669T1 (de) | Verwendung von pregnanderivaten zur behandlung von tumoren | |
DE69816244D1 (de) | Verwendung von 2-Aryl-3-aroylbenzo(b)thiophene zur Behandlung des Oestrogenenthaltungssyndroms | |
DE69301750D1 (de) | Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose | |
DE69924741D1 (de) | Verwendung einer zusammensetzung zur herstellung eines arzneimittels zur vorbeugung und behandlung von parodontitis | |
DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
DE60224884D1 (de) | Verfahren zur herstellung von 3, 3', 6, 6'-tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'-tetraalkylen-5, 5'-dihalo-2, 2' biphenolen | |
ATE230741T1 (de) | 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen | |
BG102222A (en) | The use of derivatives of the sulphaminic acid, acylsulphanomides or sulphamoylcarbamates for the preparation of a medicament for reducing lipoprotein levels | |
DE69924284D1 (de) | Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten | |
DE69609541D1 (de) | Verwendung von 6,7-substituierten-2-Aminotetraline zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von septischem Schock, und antipyretischer und antientzündlicher Zusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent |